A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
By M. Filipits, M. Rudas, R. Jakesz, P. Dubsky, F. Fitzal, C. Singer, O. Dietze, R. Greil, Andrea Jelen, P. Sevelda and 17 more. Clinical Cancer Research, 2011
652 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/9259c2c3dd98f86edba4f094ebac02c6a6bf4824
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization (2012, background): “However, some of the gene tests for breast cancer stratify patients into a low risk and a high group (Mammaprint [25] and Endopredict [26]), while other additionally introduce a medium risk group (Oncotype DX [27]).”